Share Price | Context Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Context Therapeutics, Inc.?

Market Cap: As of Jun 18, Context Therapeutics, Inc. has a market capitalization of 51.78 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Context Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -27.63 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 95.27 million and total assets of 98.13 million.

Q: What does Context Therapeutics, Inc. do?

Overview:Context Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)Market cap: USD 51.78 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.98Return on Equity: -30.37%Price to Book: 0.57Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Q: Is Context Therapeutics, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for Context Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a bullish stance on the weekly chart but are mildly bearish on the monthly. Moving averages show a mildly bearish trend on the daily timeframe. The KST is bullish weekly but bearish monthly, and Dow Theory reflects a mildly bullish stance on both weekly and monthly charts. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 19.62% and 14.64% respectively, but has significantly underperformed over the longer terms, with a year-to-date return of -4.76% compared to the S&P 500's 12.22%, and a one-year return of -48.98% versus 17.14%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.

Results Declared: Context Therapeutics, Inc. has declared results on 06 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

121.64 k

Shareholding (Mar 2026)

FII

13.99%

Held by 15 FIIs

DII

50.89%

Held by 13 DIIs

Promoter

29.16%

How big is Context Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Context Therapeutics, Inc. has a market capitalization of 51.78 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -27.63 million for the latest four quarters. As of December 2024, the company reported shareholder's funds of 95.27 million and total assets of 98.13 million.

View full answer

What does Context Therapeutics, Inc. do?

22-Jun-2025

Context Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of $51.78 million and a recent net profit loss of $5 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -30.37%.

View full answer

Is Context Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Context Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 in the short term but significantly underperformed over the longer term.

View full answer

Compare Context Therapeutics, Inc. with Similar Stocks

KALA BIO, Inc.Indaptus Therapeutics, Inc.NRX Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 281 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.05

Return on Equity

-36.13%

Price to Book

3.84

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.39%

6 Months

112.5%

1 Year

207.81%

2 Years

31.49%

3 Years

293.39%

4 Years

61.9%

5 Years

0.0%

Context Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-215.08%

EBIT to Interest (avg)

-2.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.28%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.84

EV to EBIT

-6.76

EV to EBITDA

-6.77

EV to Capital Employed

-56.06

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-36.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (5.96%)

Foreign Institutions

Held by 15 Foreign Institutions (13.99%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -89.13% vs -24.32% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-5.50",
          "chgp": "-69.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.70",
          "val2": "-4.60",
          "chgp": "-89.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -35.21% vs -11.25% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-39.60",
          "val2": "-29.90",
          "chgp": "-32.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.10",
          "val2": "-26.70",
          "chgp": "-35.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.30

-5.50

-69.09%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.70

-4.60

-89.13%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -89.13% vs -24.32% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-39.60

-29.90

-32.44%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-36.10

-26.70

-35.21%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -35.21% vs -11.25% in Dec 2024

All Annual Results

Company CV

About Context Therapeutics, Inc.

Context Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available